Arrowhead Pharmaceuticals Corp (ARWR)

5.80 +0.26 (4.69%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/1/18 *Est.)

Latest Headlines

Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22, 2018 7:34 AM - StreetInsider Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22, 2018 7:30 AM - BizWire Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT February 15, 2018 1:34 PM - StreetInsider Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15, 2018 1:32 PM - BizWire Arrowhead Pharmaceuticals Corp (ARWR) Treatment of Alpha-1 antitrypsin Deficiency Receives FDA Orphan Status February 15, 2018 12:05 PM - StreetInsider Arrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15, 2018 7:31 AM - StreetInsider Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15, 2018 7:30 AM - BizWire Arrowhead Research (ARWR) PT Raised to $4 at B.Riley/FBR February 12, 2018 7:38 AM - StreetInsider Arrowhead Research (ARWR) PT Raised to $5 at Cantor Fitzgerald Citing a Stronger Balance Sheet February 12, 2018 5:51 AM - StreetInsider Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31 February 9, 2018 4:15 PM - SEC Filing Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 09 February 9, 2018 4:07 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 2c February 9, 2018 4:00 PM - StreetInsider Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results February 9, 2018 4:00 PM - BizWire Form SC 13G ARROWHEAD PHARMACEUTICAL Filed by: OppenheimerFunds, Inc. February 6, 2018 1:02 PM - SEC Filing Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results February 2, 2018 4:00 PM - BizWire Form 3 ARROWHEAD PHARMACEUTICAL For: Jan 25 Filed by: Li Zhen January 29, 2018 7:52 PM - SEC Filing Form DEFA14A ARROWHEAD PHARMACEUTICAL January 25, 2018 5:06 PM - SEC Filing Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Mar 16 January 25, 2018 4:53 PM - SEC Filing Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 18 January 22, 2018 5:25 PM - SEC Filing Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million January 22, 2018 4:00 PM - BizWire Form 424B5 ARROWHEAD PHARMACEUTICAL January 19, 2018 5:22 PM - SEC Filing Pre-Open Movers 01/18: (ESIO) (GNC) (NBEV) Higher; (ARWR) (PRTK) (ALB) Lower (more...) January 18, 2018 9:31 AM - StreetInsider Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share January 18, 2018 9:07 AM - StreetInsider Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18, 2018 9:00 AM - BizWire After-Hours Movers 01/17: (ESIO) (PTC) (AES) Higher; (ARWR) (PRTK) (IIPR) Lower (more...) January 17, 2018 6:09 PM - StreetInsider Form 424B5 ARROWHEAD PHARMACEUTICAL January 17, 2018 5:17 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Proposed Underwritten Offering of Common Stock January 17, 2018 4:01 PM - StreetInsider Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17, 2018 4:01 PM - BizWire B.Riley/FBR Starts Arrowhead Research (ARWR) at Neutral January 5, 2018 7:38 AM - StreetInsider Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: FRYKMAN EDWARD W January 3, 2018 8:08 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: Waddill William D. January 3, 2018 7:47 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: PERRY MICHAEL S January 3, 2018 7:43 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: GIVEN DOUGLAS B January 3, 2018 7:39 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: Leone Peter Brian January 3, 2018 7:37 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: O'Brien Patrick January 3, 2018 7:32 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: Myszkowski Kenneth Allen January 3, 2018 7:28 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: GIVEN BRUCE D January 3, 2018 7:26 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Jan 01 Filed by: Anzalone Christopher Richard January 3, 2018 7:23 PM - SEC Filing Form 3 ARROWHEAD PHARMACEUTICAL For: Dec 20 Filed by: Waddill William D. December 27, 2017 5:15 PM - SEC Filing Form 8-K ARROWHEAD PHARMACEUTICAL For: Dec 20 December 27, 2017 4:06 PM - SEC Filing Arrowhead Pharmaceuticals Corp (ARWR) Appoints William Waddill to Board of Directors December 27, 2017 4:00 PM - StreetInsider Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors December 27, 2017 4:00 PM - BizWire Arrowhead Pharmaceuticals Corp (ARWR) Files for Clearance to Start Phase 1/2 Study of ARO-HBV December 22, 2017 7:33 AM - StreetInsider Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV December 22, 2017 7:30 AM - BizWire Arrowhead Pharmaceuticals Corp (ARWR) Announces Filing of Regulatory Clearance to Begin Phase 1 Study of ARO-AAT December 20, 2017 7:31 AM - StreetInsider Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT December 20, 2017 7:30 AM - BizWire Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4) December 18, 2017 6:27 PM - BizWire Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30 December 12, 2017 4:13 PM - SEC Filing Form 8-K ARROWHEAD PHARMACEUTICAL For: Dec 12 December 12, 2017 4:06 PM - SEC Filing Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results December 12, 2017 4:00 PM - BizWire Form SC 13D/A ARROWHEAD PHARMACEUTICAL Filed by: Silence Therapeutics plc December 8, 2017 5:21 PM - SEC Filing Arrowhead (ARWR) Presents New Data Showing Sustained Host Response in HBV Patients Following RNAi Therapy December 6, 2017 8:46 AM - StreetInsider Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy December 6, 2017 7:00 AM - BizWire Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results December 5, 2017 4:00 PM - BizWire Form SC 13D ARROWHEAD PHARMACEUTICAL Filed by: Silence Therapeutics plc December 1, 2017 5:03 PM - SEC Filing Form SC 13D/A ARROWHEAD PHARMACEUTICAL Filed by: NOVARTIS AG November 28, 2017 11:06 AM - SEC Filing Piper Jaffray Upgrades Arrowhead Research (ARWR) to Overweight November 27, 2017 3:54 AM - StreetInsider Full Article List